show Abstracthide AbstractThe World Health Organization (WHO) currently classifies carbapenem-resistant Enterobacterales (CRE) as one of the top three most dangerous multidrug-resistant pathogens. With the incidence of infections from CRE increasing dramatically since the first reported case in 1996, it is considered a significant public health threat. The Consortium on Resistance Against Carbapenems in Klebsiella and other Enterobacteriaceae 2 (CRACKLE-2) Study was designed to provide additional observational data to help design future randomized clinical trials on both therapeutics and diagnostics for multi-drug resistant organism (MDRO) infections.